依诺肝素

依诺肝素与普通肝素在联合纤溶疗法治疗ST段抬高型心肌梗死中作用的比较

Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction

急性冠状动脉综合征介入治疗前应用依诺肝素有效性和安全性研究目的研究低频高能超声溶解急性心肌梗死（AMI）闭塞相关血管血栓的有效性和安全性。

The safety and efficacy of pre-treatment with enoxaparin ( Clexane ) in acute coronary syndrome patients undergoing percutaneous coronary intervention Objective To evaluate the safety and efficacy of clinical application of coronary thrombolysis by ultrasound ( CTU ) to the infarct related artery ( IRA ) vessels in AMI .

抗Xa因子活性测定评价依诺肝素在心导管室中应用的安全性和有效性

Evaluation of the safety and efficacy of enoxaparin administration in the cardiac catheter laboratory by measurement of factor Xa activity

低分子肝素&依诺肝素在经皮冠状动脉介入治疗围手术期的应用

The application of low molecular weight heparin-enoxaparin in percutaneous coronary intervention

依诺肝素治疗老年不稳定型心绞痛30例近期疗效观察

Short-term efficacy observation of Enoxaparin in 30 elderly patients with unstable angina

那屈肝素也有相关研究，但主要是关于依诺肝素的研究比较多。

Nadroparin has been studied as well , but the main results have been achieved with enoxaparin .

他还会继续等待针对依诺肝素和未分解肝素作用的具有随机安慰剂对照的临床研究的结果。

He awaits the results of a randomized , placebo-controlled clinical trial of enoxaparin versus unfractionated heparin .

由依诺肝素继发的湿疹样斑疹

Eczema-like plaques secondary to enoxaparin

急性冠状动脉综合征高危患者围介入期应用依诺肝素和那屈肝素有效性和安全性的比较

Safety and efficacy of enoxaparin and nadroparin in high risk patients with ACS during percutaneous coronary intervention

不管是否服用氯吡格雷，依诺肝素都较普通肝素具有更明显的安全性和有效性。

The significantly improved safety and efficacy profile of enoxaparin versus unfractionated heparin was maintained regardless of clopidogrel administration .

这导致与依诺肝素相比，包括死亡、心梗、卒中和出血等方面的疗效更好。

This led to a better efficacy in terms of death , MI , stroke , and bleeding versus enoxaparin .

研究了影响酯化率与成环率的主要因素，控制合适的酯化、解聚和纯化条件，得到的依诺肝素钠成品符合欧洲药典标准。

Major factors that affected the degree of esterification and1,6-anhydro ring formation were studied to produce the title compound which met the European Pharmacopoeia standard .

安全性结果：在325例随机入选的受试者中，316例应用了研究药物，（利伐沙班组160例，依诺肝素组156例）并入选安全性分析人群。

Result of safety : Of the 325 randomized subjects , 316 were exposed to study drug Rivaroxaban : 160 , enoxaparin : 156 and included in the safety population .